[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585663":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":29,"responsibleParty":51,"collaborators":10,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":55,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":10,"studyType":67,"phases":10,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"group 1",null,"The group will include subjects diagnosed with ankylosing spondylitis (AS) according to the modified 1984 New York criteria, who exhibit symptoms of active disease at both screening and baseline, as indicated by a BASDAI score of ≥ 4. Eligible participants must be biologic-naive, meaning they have no prior use of TNF inhibitors (TNFi), JAK inhibitors (JAKi), or IL-17 inhibitors (IL-17i). Additionally, patients must be deemed suitable for secukinumab treatment as per the labeling guidelines set by the Ministry of Food and Drug Safety. The study will focus on individuals with a time since AS diagnosis of less than 5 years, aged between 18 and 40 years.",[13],"Drug: Secukinumab",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Secukinumab","This is a prospective observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Novartis Pharmaceuticals, MD","CONTACT","+41613241111","thomas.paul@novartis.com",{"name":27,"role":23,"phone":10,"phoneExt":10,"email":28},"Novartis Pharmaceuticals","minsoo.jee@novartis.com",[30,43],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":10,"cosmosGeoPoint":37,"geoPoint":42,"contacts":10},"Novartis Investigative Site","RECRUITING","Jinju","Gyeongsangnam-do","52727","South Korea",{"type":38,"coordinates":39},"Point",[40,41],128.08472,35.19278,{"lat":41,"lon":40},{"facility":31,"status":32,"city":44,"state":10,"zip":45,"country":36,"countryCode":10,"cosmosGeoPoint":46,"geoPoint":50,"contacts":10},"Busan","49201",{"type":38,"coordinates":47},[48,49],129.03004,35.10168,{"lat":49,"lon":48},{"type":52,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100585663","real-world-study-on-secukinumab-effectiveness-in-biologic-nave-ankylosing-spondylitis-as-patients-in-korea-100585663",false,"NCT06905288","Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.","Real-world Observational Study to Evaluate the Effectiveness of Secukinumab in Biologic-naive Ankylosing Spondylitis Patients in Korea","ONSET","Inclusion Criteria:\n\n1. Subjects diagnosed with ankylosing spondylitis (AS), as defined by the modified 1984 New York criteria\n2. Subjects who have symptoms of active disease at screening and baseline, as evidenced by BASDAI score of ≥ 4\n3. Subjects who have never used TNFi, JAKi, or IL-17i drugs before\n4. Patients suitable for secukinumab treatment within the scope of labeling by the Ministry of Food and Drug Safety\n5. Subjects who have a time of less than 5 years since AS diagnosis\n6. Subjects who are above the age of 18 years and below 40years old\n7. Subjects who give informed consent form to participate in the study\n\nExclusion Criteria:\n\n1. Subjects who are in a medical or psychological condition which may prevent them from participating in the study for the study period(28±4 weeks)\n2. Subjects who have congenital\u002Ftraumatic spinal deformities\n3. Subjects currently enrolled in other clinical studies\n4. Subjects who have any contraindications to secukinumab treatment","ALL","18 Years","40 Years",{"count":65,"type":66},70,"ESTIMATED","OBSERVATIONAL","This is an observational study to evaluate the effectiveness and safety of secukinumab in participants with AS who have never used TNFi, JAKi, or IL-17i drugs before.",[70],"Ankylosing Spondylitis",[17,70,72,73,74,75,76,77,78,79],"Biologic Naive","Real World Study","Korea","Rheumatology","AS Research","Rheumatic Disease","Biologics","Clinical Effectiveness","2026-02-19",{"date":82,"type":83},"2026-02-23","ACTUAL",{"date":85,"type":83},"2025-04-02",{"date":87,"type":66},"2026-12-31",{"name":27,"class":6},2]